NCT01649804View on ClinicalTrials.gov

A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Rheumatoid Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg intravenously every 4 weeks for 104 weeks

Trial Locations (3)

1027

Budapest

3300

Eger

4032

Debrecen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01649804 - A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter